Bedside Snapshot
- Use It For
- Acute cardiogenic pulmonary edema (adjunct); acute decompensated heart failure (ADHF) with fluid overload; edema from heart failure, cirrhosis or renal disease
- Adult Dose
- Pulmonary edema: 40 mg IV over 1–2 min; 80 mg IV if no response in 1 hr
- ADHF on a home loop diuretic: IV 1–2.5 times the daily oral dose
- Edema: 20–40 mg IV/IM; raise by 20 mg no sooner than every 2 hr (no labeled IV max)
- Pediatric Dose
- 1 mg/kg IV/IM over 1–2 min; raise by 1 mg/kg no sooner than every 2 hr (max 6 mg/kg/dose). PO 2 mg/kg. Premature infants: max 1 mg/kg/day
- Onset / Duration
- IV: ≤5 min (peak 30 min) / about 2 hr; IM: slightly later; PO: within 1 hr / 6–8 hr; subcut (Furoscix): up to 6–8 hr
- Do Not Give / Hold If
- Anuria; prior furosemide hypersensitivity; cardiogenic shock, severe hypotension or hypovolemia; hepatic coma or severe electrolyte depletion until corrected
- Watch For
- Volume depletion (hypotension, rising creatinine); low K⁺ and Mg²⁺ (ectopy, U waves); ototoxicity (tinnitus after fast pushes); urinary retention (enlarged prostate)
- Reversal / Rescue
- No antidote: stop the drug; replace fluid and electrolytes guided by BP, urine output and serum K⁺, Mg²⁺ and Na⁺; catheterize for outlet obstruction
- Must Remember
- Confirm cardiogenic pulmonary edema first: furosemide harms patients with pneumonia, COPD, sepsis or dehydration. Push IV over 1–2 min; infuse doses above about 80 mg no faster than 4 mg/min
Indications
Emergency & Prehospital
- Acute cardiogenic pulmonary edema: Labeled as adjunctive therapy. Give it alongside oxygenation, CPAP or noninvasive ventilation and nitroglycerin per protocol. It never replaces them. Prehospital use varies by protocol and needs a secure diagnosis.
ED / ICU / Transport
- ADHF with significant fluid overload: Give the IV loop diuretic promptly. The 2022 AHA/ACC/HFSA heart failure guideline rates it Class 1. The 2026 ESC heart failure guideline also recommends loop diuretics for congestion.
- Diuretic resistance: When the patient stops responding, go higher on IV loop doses or add a second diuretic (AHA/ACC/HFSA Class 2a). The 2026 ESC guideline adds a thiazide-type diuretic or short-term IV acetazolamide for patients already on loop diuretics (Class IIa). In the DOSE trial, bolus and continuous infusion performed equally.
- ICU fluid overload, including with acute kidney injury (AKI): The same drug doubles as the furosemide stress test, which predicts AKI progression (off-label).
- Hyperkalemia in patients who make urine: An adjunct that raises renal K⁺ loss. It is never a substitute for membrane stabilization and shifting (off-label).
- Hypermagnesemia with adequate renal function: An adjunct that raises renal Mg²⁺ loss. Furosemide and saline diuresis both enhance Mg excretion, per Musso 2009. Maintain volume with IV fluids. IV calcium covers toxicity, and dialysis is for severe cases (off-label).
- Hypercalcemia: Not routine. Reserve it for volume overload during saline hydration (off-label).
Other Uses
- Edema from heart failure, cirrhosis or renal disease, including nephrotic syndrome: adults and children (PO, IV, IM)
- Outpatient congestion in chronic heart failure or chronic kidney disease (CKD): subcutaneous furosemide, short term only
- Hypertension: oral, alone or with other agents
Dosing & Administration
Doses vary by protocol; follow local protocols and medical direction.
Available Forms
- Injection: 10 mg/mL single-dose vials: 20 mg/2 mL, 40 mg/4 mL, 100 mg/10 mL. This is the form EMS, the ED, the ICU and transport carry.
- Tablets: 20 mg, 40 mg, 80 mg
- Oral solution: 10 mg/mL and 8 mg/mL (40 mg/5 mL)
- Subcutaneous: Furoscix 80 mg/mL autoinjector (80 mg) or 80 mg/10 mL (8 mg/mL) cartridge for an on-body infusor; Lasix ONYU 80 mg/2.67 mL cartridge for its own on-body infusor
Adult Dosing
| Indication | Dose & Route | Repeat / Max | Notes |
|---|---|---|---|
| Acute pulmonary edema | 40 mg IV over 1–2 min | No response within 1 hr: 80 mg IV over 1–2 min; then per the ADHF row | Labeled adjunctive dose |
| Edema: IV/IM, loop-naive | 20–40 mg IV/IM; IV over 1–2 min | Repeat or raise by 20 mg no sooner than 2 hr after the last dose; then once or twice daily; no labeled IV max: titrate to response | About half the equivalent oral dose |
| ADHF, already on a loop diuretic | IV dose 1–2.5 times the total daily home oral dose (as furosemide) | Poor response (spot urine Na⁺ <50–70 mEq/L at about 2 hr or urine output <100 mL/hr at 6 hr): double the next dose; usual practice ceiling 400–600 mg/day (no labeled IV max) | DOSE trial: 1 or 2.5 times the home dose as the 24-hr total, split into boluses every 12 hr or run as an infusion; protocols differ on whether the multiple is per dose or per day. Doses above about 80 mg: infuse ≤4 mg/min. Urine-Na⁺-guided escalation is optional: the 2026 ESC guideline says it may be considered (Class IIb) |
| Edema: oral | 20–80 mg PO once | Same dose or 20–40 mg more no sooner than 6–8 hr later; then once or twice daily; max 600 mg/day | Above 80 mg/day long term: close lab monitoring |
| Hypertension: oral | 40 mg PO twice daily | No labeled max: add other agents if inadequate | Cut other antihypertensives by ≥50% when adding |
| Edema: subcutaneous (Furoscix), chronic HF or CKD | 80 mg subcut: autoinjector over about 10 sec, or on-body infusor 30 mg over 1 hr then 12.5 mg/hr for 4 hr | One 80 mg device per dose; not for chronic use | Abdomen only; switch to oral when practical. Lasix ONYU: same infusor schedule, chronic HF only |
| Furosemide stress test (ICU, off-label) | 1 mg/kg IV (loop-naive) or 1.5 mg/kg IV (loop diuretic in the prior 7 days) | Single dose; urine output <200 mL in 2 hr predicts severe AKI | Prognostic test in euvolemic early AKI only. Replace urine output mL for mL every hour with lactated Ringer's or 0.9% sodium chloride for 6 hr unless net fluid loss is intended (mean output was over 1.3 L in 6 hr); monitor urine output, HR and BP closely |
Pediatric Dosing
| Indication | Dose (per kg) & Route | Max Single / Max Total | Notes |
|---|---|---|---|
| Edema: IV/IM | 1 mg/kg IV/IM over 1–2 min | Raise by 1 mg/kg no sooner than 2 hr after the last dose; max 6 mg/kg/dose | Labeled dosing. In larger children, check the per-kg dose against the usual adult initial dose (20–40 mg) and follow the local pediatric protocol; see weight-based dosing |
| Edema: oral | 2 mg/kg PO once | Raise by 1–2 mg/kg no sooner than 6–8 hr later; max 6 mg/kg/dose | Maintain at lowest effective dose |
| Premature infants | Neonatal/NICU protocol only (specialist use) | Max 1 mg/kg/day | See Special Populations |
Continuous Infusion
| Setting | Example Concentration | Start | Titrate | Usual Range / Max |
|---|---|---|---|---|
| Adult ADHF or ICU fluid overload | Concentration set by institutional protocol, example (institution-specific); diluent 0.9% sodium chloride, lactated Ringer's or D5W adjusted to pH above 5.5 | IV bolus first, then rate per institutional protocol. Example (DOSE trial): the total daily IV dose (1 or 2.5 times the home oral dose) run over 24 hr | By hourly urine output and natriuresis | Usual practice ceiling 400–600 mg/day; never faster than 4 mg/min |
Pediatric infusions: PICU or cardiac ICU protocol only. Specialists run them.
Preparation & Administration
- Push rate: Undiluted IV over 1–2 min. A fast push is the main avoidable cause of ototoxicity.
- High doses: In practice, single doses above about 80 mg get a controlled infusion. The label sets no threshold. Run it no faster than 4 mg/min. 200 mg takes at least 50 min.
- Dilution: Use 0.9% sodium chloride, lactated Ringer's or D5W adjusted to pH above 5.5. Below pH 7, furosemide may precipitate.
- IM: Undiluted. Expect transient injection-site pain.
- Appearance: do not use discolored solution or solution with particles
- Pump: infusions on a smart pump in mg/hr
- Subcutaneous devices: Abdomen only, and rotate sites. A removed on-body infusor cannot be restarted.
Dosing Notes:
- Roughly equal doses: 40 mg PO furosemide, 20 mg IV furosemide, 1 mg bumetanide and 20 mg torsemide.
- Renal and hepatic details sit under Special Populations.
Contraindications & Precautions
Contraindications
- Anuria
- History of hypersensitivity to furosemide
- Subcutaneous products (Furoscix, Lasix ONYU): hypersensitivity to any formulation component; on-body infusors: hypersensitivity to medical adhesives
Precautions
- Cirrhosis with ascites: Sudden fluid and electrolyte shifts can trigger hepatic encephalopathy. Start in hospital with small doses.
- Older adults: Too much diuresis can cause circulatory collapse, thrombosis and embolism.
- Ototoxicity risk: Fast pushes, severe renal impairment, high doses, hypoproteinemia and aminoglycosides all raise it.
- Urinary outflow obstruction: Prostatic hyperplasia can tip into acute retention.
- Sulfonamide allergy: Cross-allergy is possible. The oral label lists it as a precaution, not a contraindication.
- High risk of contrast nephropathy: Compared with IV hydration alone, furosemide makes renal function worse after radiocontrast. Do not use it as prophylaxis.
- Other: hyperglycemia; gout; lupus flare
Hold / Reassess If
- Cardiogenic shock, symptomatic hypotension or hypovolemia: hold
- Rising BUN and creatinine with oliguria in progressive renal disease: stop
- K⁺ <3.5 mEq/L or low Mg²⁺: replete before further doses where possible
- New tinnitus, hearing loss, confusion or asterixis: stop and notify
FDA Boxed Warning: Labels for tablets, oral solution and older-format injections warn that excessive doses cause profound diuresis, with water and electrolyte depletion. Dosing needs careful medical supervision.
Adverse Effects & Toxicity
Common
- Electrolyte loss (most common): low K⁺, Na⁺, Mg²⁺ and Ca²⁺; hypochloremic alkalosis
- Orthostatic hypotension and dizziness
- Hyperglycemia and hyperuricemia
- Muscle spasm, weakness; photosensitivity
Serious / Life-Threatening
| Effect | Recognition | Management |
|---|---|---|
| Volume depletion | Hypotension, tachycardia, rising BUN and creatinine; thrombosis in older adults | Stop; replace fluid; recheck labs |
| Hypokalemia, hypomagnesemia | Low K⁺ or Mg²⁺, ectopy, U waves; digoxin toxicity more likely | Replete K⁺ and Mg²⁺ (magnesium sulfate); ECG monitoring |
| Ototoxicity | Tinnitus, hearing loss, vertigo; may be permanent | Stop; review push rate, dose, renal function, aminoglycosides |
| Hepatic encephalopathy | Confusion or asterixis in cirrhosis | Stop; correct K⁺ and volume |
| Acute urinary retention | Distended bladder, no output despite diuresis | Bladder scan and catheter |
| Severe hypersensitivity | Anaphylaxis; SJS/TEN, DRESS; interstitial nephritis | Stop permanently; IM epinephrine for anaphylaxis |
| Blood dyscrasias (rare) | Agranulocytosis, aplastic anemia, low platelets | Stop; hematology input |
Overdose & Toxicity Management
- Signs: dehydration, hypotension, hypokalemia, hypochloremic alkalosis
- Management: stop; replace fluid and electrolytes; frequent electrolytes, CO₂ and BP; cardiac monitoring; drain an obstructed bladder
- Antidote: none. Hemodialysis does not speed elimination.
Monitoring
| Parameter | When / How Often | Target / Act If |
|---|---|---|
| Clinical: urine output | Hourly for 6 hr after an IV dose in ADHF | <100 mL/hr at 6 hr: double the next IV dose |
| Clinical: spot urine sodium | About 2 hr after the first IV dose | <50–70 mEq/L: inadequate response; intensify |
| Clinical: BP and perfusion | Before each dose and after IV doses | Hypotension or hypoperfusion: hold, reassess volume |
| Clinical: weight, intake and output | Daily weight; intake and output every shift | Faster loss than planned or orthostasis: reduce or hold |
| Clinical: hearing, mental status | Each assessment, especially high doses | Tinnitus or hearing loss: stop. Confusion in cirrhosis: stop, check electrolytes |
| Laboratory: K⁺, Mg²⁺, Na⁺, HCO₃⁻ | Baseline, then frequently during IV diuresis | |
| Laboratory: BUN, creatinine | Baseline and with electrolytes | Rising creatinine with oliguria in progressive renal disease: stop |
| Laboratory: glucose, uric acid, calcium | Periodically; glucose more often in diabetes | Hyperglycemia or low Ca²⁺: adjust therapy |
| Drug Levels: lithium, digoxin | When co-prescribed | |
| Pediatrics: renal ultrasound | Use in the first year of life (especially preterm) and chronic use under 4 years | Nephrocalcinosis: review need and cumulative dose |
Interactions & Compatibility
Clinically Significant Interactions
| Drug / Class | Effect | What To Do |
|---|---|---|
| Aminoglycosides, cisplatin, ethacrynic acid | Additive ototoxicity and nephrotoxicity | Avoid except when life-threatening; slow pushes; monitor hearing and renal function |
| Lithium, high-dose salicylates, methotrexate and other tubularly secreted drugs | Reduced renal clearance (competition for tubular secretion); toxicity at lower doses. High-dose methotrexate may also raise furosemide toxicity | Avoid lithium; if unavoidable, check lithium levels. Watch for salicylate toxicity; monitor drug levels |
| ACE inhibitors, ARBs, nitroglycerin, other antihypertensives | Severe hypotension; renal failure with ACE inhibitors or ARBs | Watch BP and creatinine; reduce doses as needed |
| Norepinephrine; neuromuscular blockers | Reduced arterial response to norepinephrine (it still works); may potentiate succinylcholine and antagonize tubocurarine | Monitor BP or MAP and titrate pressors; monitor neuromuscular blockade |
| NSAIDs, including ketorolac | Blunted natriuresis; rising creatinine and K⁺ | Avoid; monitor diuretic response and renal function |
| Thiazide-type diuretics (metolazone, chlorothiazide), corticosteroids, digoxin | Thiazides: synergistic natriuresis with marked K⁺, Na⁺, Mg²⁺ loss. Corticosteroids add K⁺ loss; low K⁺ raises digoxin toxicity risk | Reserve thiazides for inadequate loop response; keep K⁺ and Mg²⁺ normal with close electrolyte monitoring |
| Sucralfate, phenytoin | Reduced furosemide effect: sucralfate lowers oral absorption; phenytoin blunts the renal action (IV and PO) and lowers oral absorption | Separate oral furosemide and sucralfate by at least 2 hr; with phenytoin, watch diuretic response and adjust the dose |
| Cephalosporins, cyclosporine, chloral hydrate | Cephalosporin nephrotoxicity; gout with cyclosporine; IV furosemide within 24 hr of chloral hydrate can cause flushing, sweating, hypertension and tachycardia | Monitor renal function and urate; avoid IV furosemide within 24 hr of chloral hydrate |
IV Compatibility
- Diluents: 0.9% sodium chloride, lactated Ringer's or D5W, pH above 5.5
- Incompatible: acidic drugs such as labetalol, ciprofloxacin and milrinone. They make furosemide precipitate. Never run them in the same infusion.
- Line: flush before and after, or use a separate line
- Verify with an institutional compatibility resource.
Special Populations
- Pediatrics: Labeled for edema (see Pediatric Dosing). Nephrocalcinosis risk applies in the first year of life and with chronic use under 4 years. Furoscix: children are approved for the on-body infusor only, at 43 kg and above. A healthcare provider or adult caregiver must apply it. The ReadyFlow autoinjector is for adults only.
- Neonates: Premature infants clear it slowly. Above 1 mg/kg/24 hr before 31 weeks postconceptional age, levels may reach the ototoxic range. Nephrocalcinosis calls for renal function and renal ultrasound monitoring. It may keep a patent ductus arteriosus open in preterm infants.
- Pregnancy: Decades of observational data show no drug-associated risk of major birth defects or miscarriage. Untreated heart failure or cirrhosis carries maternal and fetal risk, too.
- Lactation: It is present in milk. Infant effects are unknown. Brisk diuresis may reduce milk production.
- Older Adults: Renal clearance is lower, yet older adults get more volume depletion and thrombosis. Start low.
- Renal Impairment: No fixed reduction. Higher doses are often needed, with single IV doses up to 160–200 mg in CKD (within 600 mg/day), and ototoxicity rises with them. Anuria is a contraindication. Hemodialysis does not remove it. See CRRT and hemodialysis.
- Hepatic Impairment: Do not start it in hepatic coma. In cirrhosis, start in hospital with small doses, usually alongside an aldosterone antagonist.
- Obesity / Dosing Weight: Adult doses are fixed, not weight-based. No specific adjustment has been established.
- Hypoalbuminemia and Nephrotic Syndrome: Less drug reaches the tubule. The effect is weaker, and ototoxicity becomes more likely. Reserve albumin co-administration for severe hypoalbuminemia.
Field & Transport Considerations
- Scope: Scope is paramedic and above, RN and critical-care transport, per local protocol. The AEMT IV list leaves it out. Prehospital IV furosemide is not a core step in pulmonary edema. Oxygen, CPAP/NIV and nitroglycerin come first. The NASEMSO model guideline is blunt: diuretics 'provide no immediate benefit for most patients and can cause significant harm'. Confirm cardiogenic pulmonary edema first. State and agency protocols vary.
- Prehospital Evidence: The FAST-FURO registry analysis found that EMS-given IV furosemide did not change in-hospital or 30-day mortality after adjustment. In-hospital mortality OR 1.080, 95% CI 0.817–1.427.
- Storage & Stability: Keep it at 20–25°C (68–77°F), with excursions to 15–30°C (59–86°F) tolerated. Protect it from light and keep it out of hot vehicles. Do not refrigerate or freeze Furoscix.
- Carried Concentration: 10 mg/mL means 40 mg is 4 mL. Per the bumetanide labels, bumetanide 1 mg ≈ furosemide 40 mg. HF tables use bumetanide 1 mg ≈ furosemide 20 mg IV instead. Confirm the drug and the mg before you draw up.
- Diuresis on the Road: Output is brisk within minutes of an IV dose. Carry a urinal or catheter. Expect orthostasis when you move the patient.
- On-Body Infusor: Remove it and the infusion stops for good. It is not MRI-compatible. Note the start time: 80 mg over 5 hr.
- Handoff Essentials: each dose, route and time, 24-hr total, infusion rate, urine output, spot urine sodium, last K⁺, Mg²⁺ and creatinine, BP trend.
Clinical Pearls
Not Every Wet Lung Is Heart Failure: Pneumonia, COPD, sepsis and dehydration all mimic pulmonary edema. Furosemide hurts those patients. Confirm the diagnosis and volume status before the first dose.
Double, Do Not Repeat: Loop diuretics only work above a tubular threshold concentration. If urine output or urine sodium shows a poor response, double the next dose. Repeating an ineffective dose does not help.
Gut Edema Blunts Tablets: Oral bioavailability averages about 50%, and it varies widely between patients. Bowel-wall edema pushes it lower still. A patient who stops responding to home tablets often responds to the same drug IV.
Ototoxicity Stack: A fast push, high doses, renal failure, hypoalbuminemia and an aminoglycoside on one patient? That is the highest hearing-loss risk. Ask about tinnitus.
Exam Discriminator, Sulfa Allergy: The oral label treats a sulfonamide allergy as a precaution, not a contraindication. The real contraindications are anuria and furosemide hypersensitivity. For the subcutaneous devices, add hypersensitivity to a formulation component and to medical adhesives.
Bolus or Drip: IV effect lasts about 2 hr. In ADHF, that means boluses at least every 12 hr or an infusion, not once daily. In the DOSE trial, 12-hourly boluses and continuous infusion gave similar symptom relief and renal outcomes. Starting a drip? Give a bolus first.
Pharmacology
Mechanism of Action
- Blocks the Na⁺-K⁺-2Cl⁻ cotransporter (NKCC2) in the thick ascending limb. Large sodium and water loss follows, and decongestion comes fast.
- More sodium reaches the distal nephron. That drives out K⁺, H⁺, Mg²⁺ and Ca²⁺, leading to hypokalemia and hypochloremic alkalosis.
- Early venodilation, largely prostaglandin-mediated, is inconsistent. In severe chronic HF, IV furosemide can first raise SVR and filling pressure through neurohormonal activation. Decongestion depends on diuresis. It does not replace nitrates for rapid preload reduction.
- The drug travels bound to albumin and must be secreted into the tubule. Hypoalbuminemia and kidney disease blunt the effect.
Pharmacokinetics
| Route | Onset | Peak | Duration |
|---|---|---|---|
| IV | ≤5 min | 30 min | About 2 hr |
| IM | Slightly later than IV | — | — |
| PO | Within 1 hr | 1–2 hr | 6–8 hr |
| Subcut (Furoscix) | — | — | Up to 6–8 hr |
- Half-life: about 2 hr. It runs longer in renal, hepatic or heart failure and in premature infants.
- Bioavailability: tablets 64% and solution 60% of IV in healthy adults, highly variable in disease; subcutaneous about 100%
- Metabolism / elimination: glucuronidation; mainly renal, largely unchanged
- Protein binding: 91–99%, mainly albumin
Names & Classification
- Generic Name
- Furosemide (former British name: frusemide)
- Brand Names
- Lasix (tablets); Furoscix and Lasix ONYU (subcutaneous); injection mainly generic
- Pharmacologic Class
- Loop diuretic (anthranilic acid derivative)
- Therapeutic Class
- Diuretic for edema and volume overload; antihypertensive
- Controlled Substance
- Not controlled
- ISMP High-Alert
- No
- Look-Alike / Sound-Alike
- Milligram confusion with bumetanide (see the bumetanide page)
References
- Hospira, Inc. (2026). Furosemide Injection, for intravenous or intramuscular use: Prescribing information. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=39fd32f2-6bb7-4a65-d298-e48d26bc80c7
- Hikma Pharmaceuticals USA. (2025). Furosemide Tablets, USP and Furosemide Oral Solution, USP: Prescribing information. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9e493331-dddd-496e-abf8-61747fb67aba
- scPharmaceuticals. (2026). Furoscix (furosemide injection) for subcutaneous use: Prescribing information. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eac958dd-8d43-e44e-e053-2995a90a4d5e
- Heidenreich, P. A., Bozkurt, B., Aguilar, D., et al. (2022). 2022 AHA/ACC/HFSA guideline for the management of heart failure. Circulation, 145(18), e895–e1032. https://doi.org/10.1161/CIR.0000000000001063
- Køber, L., Adamo, M., Ruwald, A.-C., Tomasoni, D., et al. (2026). 2026 ESC guidelines for the management of heart failure. European Heart Journal, 47(38), 5346–5457. https://doi.org/10.1093/eurheartj/ehag100
- Wu, L., Rodriguez, M., El Hachem, K., & Krittanawong, C. (2024). Diuretic treatment in heart failure: A practical guide for clinicians. Journal of Clinical Medicine, 13(15), 4470. https://doi.org/10.3390/jcm13154470
- Chawla, L. S., Davison, D. L., Brasha-Mitchell, E., Koyner, J. L., et al. (2013). Development and standardization of a furosemide stress test to predict the severity of acute kidney injury (landmark derivation study). Critical Care, 17(5), R207. https://doi.org/10.1186/cc13015
- Miró, Ò., Harjola, P., Rossello, X., et al. (2021). The FAST-FURO study: Effect of very early administration of intravenous furosemide in the prehospital setting to patients with acute heart failure attending the emergency department. European Heart Journal: Acute Cardiovascular Care, 10(5), 487–496. https://doi.org/10.1093/ehjacc/zuaa042
- Felker, G. M., Lee, K. L., Bull, D. A., Redfield, M. M., Stevenson, L. W., Goldsmith, S. R., et al. (2011). Diuretic strategies in patients with acute decompensated heart failure (landmark trial). New England Journal of Medicine, 364, 797–805. https://doi.org/10.1056/NEJMoa1005419
- SQ Innovation, Inc. (2025). Lasix ONYU (furosemide injection) 80 mg/2.67 mL for subcutaneous use with Infusor: Prescribing information (updated November 14, 2025). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cb27654f-c7a1-4796-ab08-60a5fa16f5c0
- Francis, G. S., Siegel, R. M., Goldsmith, S. R., Olivari, M. T., Levine, T. B., & Cohn, J. N. (1985). Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure: Activation of the neurohumoral axis (landmark study). Annals of Internal Medicine, 103(1), 1–6. https://doi.org/10.7326/0003-4819-103-1-1
- Musso, C. G. (2009). Magnesium metabolism in health and disease. International Urology and Nephrology, 41(2), 357–362. https://doi.org/10.1007/s11255-009-9548-7
Medical Disclaimer
- For Educational Purposes Only: This content is intended for educational reference and should not be used for clinical decision-making.
- Not a Substitute for Professional Judgment: Always consult your local protocols, institutional guidelines, and supervising physicians.
- Verify Before Acting: Users are responsible for verifying information through authoritative sources before any clinical application.
AI Assistance Notice
AI was used to assist in organizing, paraphrasing, and formatting this information.